Comparison of Biomerica and TerrAscend Financial Metrics
2 reports, 2 independent
Updated Oct 18
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biomerica and TerrAscend are both classified as small-cap healthcare companies. An analysis comparing the two businesses detailed institutional ownership, profitability, and valuation metrics. Biomerica has a consensus target price of $9.00, suggesting a potential upside of 391.80% according to analysts.
From tickerreport.com
Why it matters
The comparison shows that Biomerica has higher earnings than TerrAscend, although Biomerica has lower gross revenue. Biomerica also has higher institutional ownership at 22.3% compared to TerrAscend's 5.8%. TerrAscend has a higher percentage of shares owned by company insiders at 31.9%.
From tickerreport.com